Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Genetics Purchases Illumina HiSeq, BeadXpress


This article was orignally published Aug. 25.

Ambry Genetics has acquired an Illumina HiSeq 2000 sequencer for its service business, along with an Illumina BeadXpress genotyping system.

The HiSeq will allow the Aliso Viejo, Calif.-based firm "to run large projects for its customers while saving costs and providing the fastest turnaround times for sequencing," according to a company statement. Ambry has provided sequencing services on the Illumina Genome Analyzer since 2007.

Ambry, which has a CAP-accredited and CLIA-certified clinical laboratory, offers both genomic services and genetic diagnostic and carrier testing.

An Illumina-certified service provider, it currently provides a variety of sequencing services on the GAIIx, including whole-genome sequencing, exome sequencing, and RNA sequencing. For targeted sequencing, the company uses the Agilent SureSelect, RainDance, and Roche NimbleGen enrichment methods.

This spring, Ambry said it was working on a sequencing-based genetic carrier screening test to assay known mutations involved in more than 90 genetic diseases (IS 5/18/2010).

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.